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Delayed-type cutaneous drug hypersensitivity is a T-cell
mediated disease; the spectrum of conditions has been
classified according to the phenotype and function of
drug antigen-specific T-cells sub-sets. Importantly, this
classification does not take into account tissue-specific
cytokines such as interleukin-17 and interleukin-22.
Both of these cytokines have been shown to play a role
in numerous physiological and pathological processes.
For example, elevated levels have been detected in
patients with psoriasis and allergic contact dermatitis.
To investigate this, we have focused on piperacillin, a
b-lactam antibiotic used for the treatment of pulmonary
exacerbations in patients with cystic fibrosis. Unfortu-
nately hypersensitivity reactions (mean onset = 9.1 days;
symptoms include maculopapular rash, fever and/or
flu-like symptoms) to this drug develop in 26-50% of
treated patients. Piperacillin-specific T-cell clones were
generated from 3 lymphocyte transformation test posi-
tive hypersensitive patients and 4 healthy donors, follow-
ing priming of naïve T-cells against piperacillin-exposed
dendritic cells, to characterize T-cell phenotype (CD and
chemokine receptor expression) and function (prolifera-
tion and secretion of cytokines/cytolytic molecules [IFNg,
13, 17, 22 by ELIspot]). Seventy six CD4+ and CD8+
clones were isolated from the hypersensitive patients and
shown to proliferate in the presence of piperacillin. Drug
stimulation was associated with the secretion of IFN-g and
IL13 from all clones. IL-22 secretion was detected from
64% and 75% of the CD4+ and CD8+ clones, respectively.
In contrast, IL17 was not detected. Naïve T-cells co-
cultured with piperacillin and autologous dendritic cells
showed concentration-dependent proliferation and
cytokine (IFNg, IL13 and IL22) secretion. CD4+ and CD8
+ clones generated from the primed T-cells also secreted
IFNg, IL13 and IL22 (CD4+ 50%, CD8+ 67%) following
piperacillin stimulation. CCR1, CCR4 and CCR10 were
expressed on all clones. Other chemokine receptors
expressed on a limited number of clones included CXCR3,
CXCR6, CCR2 and CCR9. In conclusion, these data show
the involvement of IL22 secreting T-cells in the pathogen-
esis of piperacillin hypersensitivity reactions in patients
with cystic fibrosis.
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